AstraZeneca (AZN) Q3 results: Revenues: $6,406M (+20.0%); Product Sales: $6,132M (+16.4%); Collaboration Revenue: $274M.
Key product sales: Tagrisso: $891M (+76%);
Lynparza: $327M (+94%); Symbicort: $613M (-1%); Nexium: $374M (-11%);
Brilinta: $416M (+24%); Farxiga: $398M (+12%); Pulmicort: $337M (+28%);
Crestor: $327M (-4%); Imfinzi: $412M; Faslodex: $205M (-20%).
Net Income: $280M (-31.0%); EPS: $0.23 (-32.4%); non-GAAP EPS: $0.99; CF Ops: $1,594M.
2019 Guidance: Product Sales: An
increase by by a low to mid-teens percentage from low double-digit
percentage; Core EPS: $3.50 – 3.70 (unch).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.